Foghorn Therapeutics Inc.
- Last sale
- Nov 12, 2026 · -1.44%
- Market cap
- $123.52M
- 59.96M shares
- Filings
- 356
Q3 2026+36.8% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+45.8% FY25 yoy
- $123.52M
- 13.1×
- 1.1×
- —
- -67.75%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $30,909,000 | reported | |
| FY 2024 | 2024-12-31 | $22,602,000 | reported | |
| FY 2023 | 2023-12-31 | $34,155,000 | reported | |
| FY 2022 | 2022-12-31 | $19,228,000 | reported | |
| FY 2021 | 2021-12-31 | $1,319,000 | reported | |
| FY 2020 | 2020-12-31 | $430,000 | reported |
Pharmaceutical preparations
Foghorn Therapeutics Inc. is the 146th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
SBFMSunshine Biopharma Inc.$36.3M4.1%16.5%$2.4METSTEarth Science Tech, Inc.$35.7M7.8%10.2%$25.9MVRCAVerrica Pharmaceuticals Inc.$35.6M370.2%50.3%$52.9MBHSTBioharvest Sciences Inc.$34.5M37.0%32.3%$39.7MZOMDFZomedica Corp.$32.0M17.4%255.6%$78.4MVSTMVerastem, Inc.$30.9M209.1%677.6%$1.1B
FHTXFoghorn Therapeutics Inc. (this company)$30.9M36.8%240.3%$123.5M
CUECue Biopharma, Inc.$27.5M195.7%96.9%$128.4MCELUCelularity Inc$26.6M51.0%345.4%$21.8MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR